ArticleHuman vaccines & immunotherapeutics2026
Healthcare resource use and costs following RSV-related hospitalizations among US adults aged 50 years and older.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV), a common virus causing acute respiratory illness (ARI), can lead to severe disease among adults aged ≥50 y. We assessed healthcare resource utilization (HRU) and costs among United States (US) adults aged ≥50 y after hospitalization with RSV-ARI. Using 2015-2023 US claims data from the Optum® Clinformatics® Data Mart, three cohorts of patients aged ≥50 y were identified: patients with ≥1 RSV-ARI episode involving hospitalization (RSV-ARI cohort), patients with ≥1 influenza-ARI episode involving hospitalization (influenza-ARI cohort), and patients without recent ARI (control cohort). HRU and costs per-patient-per-month (PPPM) were assessed at 30 d, 3 months, and 1 y post-index. Adjusted regression models compared outcomes across cohorts. Overall, 14,759 patients were included in the RSV-ARI cohort, 77,468 in the influenza-ARI cohort, and 73,795 in the control cohort. The RSV-ARI cohort had significantly higher HRU vs. controls within 1 y post-index; adjusted incidence rate ratios (95% confidence interval) 30 d through 1 y post-index ranged from 81.07 (75.85, 86.65) to 11.56 (11.20, 11.93) for inpatient stays, 5.93 (5.58, 6.30) to 2.19 (2.09, 2.29) for emergency department visits, and 1.99 (1.95, 2.04) to 1.78 (1.75, 1.81) for outpatient visits. Adjusted total costs PPPM were higher for the RSV-ARI cohort vs. controls post-index (difference at 30 d: $37,025 [$36,345, $37,704]; 1 y: $6,699 [$6,476, $6,922]). HRU and costs among patients aged ≥50 y with RSV-ARI were higher vs. controls and generally similar between the RSV-ARI and influenza-ARI cohorts, demonstrating economic burden of severe RSV disease and the importance of RSV prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.